产品
编 号：F117057
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 1313206-42-6
产品详情
生物活性：
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).
体内研究：
Polatuzumab vedotin (0.3, 1, 3, 6, 12 mg/kg; i.v.; once) shows anti-tumor in a mouse tumour xenograft model of human diffuse large B‐cell lymphoma WSU‐DLCL2.Animal Model:SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2)
Dosage:0.3, 1, 3, 6, 12 mg/kg
Administration:I.v.; once
Result:Showed dose-dependent tumour growth inhibition.
Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL).
体内研究：
Polatuzumab vedotin (0.3, 1, 3, 6, 12 mg/kg; i.v.; once) shows anti-tumor in a mouse tumour xenograft model of human diffuse large B‐cell lymphoma WSU‐DLCL2.Animal Model:SCID mice (human diffuse large B-cell lymphoma WSU-DLCL2)
Dosage:0.3, 1, 3, 6, 12 mg/kg
Administration:I.v.; once
Result:Showed dose-dependent tumour growth inhibition.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备